Treatment of chronic active antibody-mediated rejection in renal transplant recipients - a single center retrospective study.

ABSTRACT:

Background

Chronic active antibody-mediated rejection is a major etiology of graft loss in renal transplant recipients. However, there is no consensus on the optimal treatment strategies.

Methods

Computerized records from Taichung Veterans General Hospital were collected to identify renal transplant biopsies performed in the past 7 years with a diagnosis of chronic active antibody-mediated rejection. The patients were divided into two groups according to treatment strategy: Group 1 received aggressive treatment (double filtration plasmapheresis and one of the followings: rituximab, intravenous immunoglobulin, antithymogycte globulin, bortezomib, or methylprednisolone pulse therapy); and group 2 received supportive treatment.

Results

From February 2009 to December 2017

SUBMITTER: Chiu HF 

PROVIDER: S-EPMC6945538 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature